Investing Profile

Alice Zhang

Angel
Chief Executive Officer at Verge Genomics
San Francisco, California
Photo of Alice Zhang, Angel
Your Intro Paths to Alice Zhang

Signal uses Gmail to reveal intro paths. Email content is never read.

Sign in with Google →

Find Alice Zhang on

cb
Current Investing Position
Angel
Investment Range
$5K - $50K
Sweet Spot
$25K
Investments On Record
14

Alice Zhang is on these Sector & Stage Rankings

Alice Zhang's Investments On Record (11)

CompanyStageDateRound SizeTotal Raised
Ochre Bio
Series AOct 2022$30M
$40M
Co-investors: Alex Morgan (Khosla Ventures), Rob Kniaz (Hoxton Ventures), Jens Eckstein (Apollo Health Ventures), Milad Alucozai (BoxOne Ventures), Aniq Kassam (FAST — by GETTYLAB)
Arpeggio Bio
Series ASep 2022$17M
SeedJan 2020$3M
$20M
Co-investors: Amit Mehta (Builders VC), Matthew De Silva (Builders VC), Milad Alucozai (BoxOne Ventures)
Osmind
Series AJul 2021$15M
SeedOct 2020$2M
$59M
Co-investors: Joshua Kushner (Thrive Capital), Derick En'Wezoh (Susa Ventures), Hammad Aslam (Susa Ventures), Stephen Hays (What If Ventures), Lachy Groom (LGF), Justin Kao (DFJ Growth), Maryanna Saenko (Future Ventures), Akshay Sriprasad
HumanFirst
Series AMay 2021$12M
SeedNov 2019$3M
$19M
Co-investors: Beth Turner (SV Angel), David Frankel (Founder Collective), Brandon Reeves (Lux Capital), Lisa Marrone (August Capital), Ambar Bhattacharyya (Maverick Capital), Ted Leonsis (Revolution), Enke Bashllari (Arkitekt Ventures), Ellen Chisa (Boldstart Ventures), Linda Xie (Scalar Capital), Zach Weinberg (Curie.Bio), Nat Turner (Operator Partners), Ashley Larson, Howie Liu, Elliott Cohen, Sylvain Carle
Multiply Labs
Series AApr 2021$20M
$20M
64x Bio
SeedNov 2020$5M
$60M
Co-investors: Milad Alucozai (BoxOne Ventures), Sander Duncan (Lifeforce Capital), Andrew Lee (Northpond Ventures), Chris Gibson
Asher Bio
Pre SeedAug 2019$150K
$220M
Co-investors: Reid Huber (Third Rock Ventures), Jeffrey Tong (Third Rock Ventures), Jake Simson (RA Capital)
Eclipse Foods
SeedApr 2019$4M
$16M
Co-investors: Seth Goldman

most interested in

Tech-Enabled Bio